|Numéro de publication||US20050048117 A1|
|Type de publication||Demande|
|Numéro de demande||US 10/962,729|
|Date de publication||3 mars 2005|
|Date de dépôt||12 oct. 2004|
|Date de priorité||3 nov. 1997|
|Autre référence de publication||CA2312234A1, CA2312234C, EP1047426A1, EP1047426A4, EP1047426B1, US6274591, US6608075, US20020028825, US20030065003, US20040162308, US20090312359, WO1999022737A1|
|Numéro de publication||10962729, 962729, US 2005/0048117 A1, US 2005/048117 A1, US 20050048117 A1, US 20050048117A1, US 2005048117 A1, US 2005048117A1, US-A1-20050048117, US-A1-2005048117, US2005/0048117A1, US2005/048117A1, US20050048117 A1, US20050048117A1, US2005048117 A1, US2005048117A1|
|Inventeurs||Joseph Foss, Michael Roizen, Jonathan Moss, Chun-Su Yuan, William Drell|
|Cessionnaire d'origine||Foss Joseph F., Roizen Michael F., Jonathan Moss, Chun-Su Yuan, William Drell|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Citations de brevets (71), Référencé par (10), Classifications (6), Événements juridiques (1)|
|Liens externes: USPTO, Cession USPTO, Espacenet|
This application is a continuation of application Ser. No. 10/278,630, filed Oct. 23, 2002; which is a divisional of application Ser. No. 09/862,169, filed May 21, 2001 (herein incorporated by reference) now U.S. Pat. No. 6,608,075; which is a continuation of application Ser. No. 09/120,703, filed Jul. 22, 1998 (herein incorporated by reference) now U.S. Pat. No. 6,274,591; which is a continuation-in-part of application Ser. No. 08/962,742, filed Nov. 3, 1997, now U.S. Pat. No. 5,972,954 the disclosures of which are herein incorporated by reference.
The present invention is directed at the treatment of certain side effects associated with the use of opioids as analgesics. In particular the present invention is directed at treating opioid-induced inhibition of gastrointestinal motility and constipation.
Opioids are effective analgesics. However, their use is associated with a number of undesirable side effects. One such effect is constipation. Opioid-induced changes in gastrointestinal motility are almost universal when these drugs are used to treat pain, and at times may limit their use, leaving the patient in pain. Common treatments of bulking agents and laxatives have limited efficacy and may be associated with side effects such as electrolyte imbalances.
One treatment for opioid side effects is the use of opioid antagonists which cross the blood-brain-barrier, or which are administered directly into the central nervous system. Opioid antagonists such as naltrexone and naloxone have been administered intramuscularly or orally to treat opioid induced side effects. Naltrexone and naloxone are highly lipid soluble and rapidly diffuse across biological membranes, including the blood-brain barrier. However, naltrexone, naloxone, nalmefene, and other opioid antagonists which may reverse many opioid side effects have a narrow therapeutic window before they are observed to reverse the desired analgesic effect of the opioid being used.
Many quaternary amine opioid antagonist derivatives, such as methylnaltrexone, do not reduce the analgesic effect of opioids. These quaternary amine opioid antagonist derivatives, which have a relatively higher polarity and reduced lipid solubility when compared to the tertiary forms of the drugs, were specifically developed to not traverse the blood-brain barrier or to traverse it at a greatly reduced rate. However, high levels of MNTX in the plasma can lead to undesirable side effects such as orthostatic hypotension.
It is desirable in the treatment of many conditions to have oral medications with prolonged effects. Such oral medications are particularly desirable for the treatment of opioid-induced side effects.
It is further desirable to develop a method for the prevention of opioid-induced inhibition of gut motility and constipation which does not counteract the analgesic effects of the opioid, or risk increased levels of pain. Ideally, such a treatment has few side effects either due to low drug toxicity or because administration of small amounts are effective and/or administration results in low circulating levels of the drug.
The present invention is directed at methods for preventing and treating opioid-induced inhibition of gut motility and constipation.
An aspect of the invention is a composition for preventing or treating opioid-induced inhibition of gastrointestinal motility comprising administering enterically coated quaternary derivatives of noroxymorphone as disclosed in U.S. Pat. No. 4,176,186 to Goldberg et al. (herein incorporated by reference) to a patient. In certain embodiments the composition is in the form of pill, tablet, capsule or granule. The preferred quaternary derivatives of noroxymorphone is methylnaltrexone.
The present invention is directed to methods for preventing and treating opioid-induced constipation and changes in gut motility via the oral administration of an enteric coated quaternary derivatives of noroxymorphone (QDNM), particularly methylnaltrexone (MNTX). Administration of non-enterically coated MNTX results in rapid absorption of MNTX through the stomach and early peak and sustained high levels of MNTX in the plasma. However, an enteric coating on the QDNM, designed to prevent dissolution and subsequent absorption of the drug in the stomach, would be expected to produce delayed elevation of plasma levels of the QDNM, and to produce a lower peak plasma level. Suprisingly, however, administration of enterically coated MNTX has been found to result in substantially lower plasma levels as compared to non-enterically coated MNTX at the same dosage level, and surprisingly and unexpectedly resulted in enhanced efficacy in the reversal of opioid-induced decreases in gastrointestinal motility. In fact, it has been found that as compared to non-enterically coated MNTX, a significantly lower dose, e.g., less than half the amount of coated MNTX can be used if enterically coated to achieve the same levels of relief of opioid-induced constipation. Moreover, such reduced dosage levels of MNTX administered with an enteric coating results in exceedingly low peak and sustained plasma levels of MNTX, greatly reducing the potential adverse side effects of the MNTX. This novel improvement in the clinical indication for use of MNTX has led to an increased therapeutic index for this drug.
When used as a treatment for the opioid- and nonopioid-induced side effects of constipation and reduction of gastrointestinal motility, orally administered, particularly if enterically coated, MNTX or other quaternary derivatives of noroxymorphone provide prolonged relief of the side effects. MNTX has been demonstrated to have the ability to block the gastrointestinal effects of opioids on motility when administered intravenously or orally. The oral administration of non-enterically coated MNTX is associated with plasma levels with an early peak (20 min) and prolonged presence (half-life of about 3 hours after single dose of 6.4 mg/kg).
Furthermore, for treatment or prevention of constipation and delayed gastrointestinal emptying, whether caused by extrinsic or endogenous opioids, enteric coating surprisingly allows for equal or better efficacy despite lower plasma levels. Idiopathic constipation, i.e., that due to causes other than exogenous administration of opioids, may be mediated by opioid sensitive mechanisms. Endogenous opioid receptors have been identified in the gut, and these receptors may modulate gut motility. Thus, administration of an opioid antagonist with peripheral action, such a methylnaltrexone or other quaternary derivatives of noroxymorphone, would block the effects of endogenous opioids.
Quaternary derivatives of noroxymorphone are described in full in Goldberg et al., (supra), and in general are represented by the formula:
wherein R is allyl or a related radical such as chlorallyl, cyclopropyl-methyl or propargyl, and X is the anion of an acid, especially a chloride, bromide, iodide or methylsulfate anion.
The presently preferred quaternary derivative of noroxymorphone is methylnaltrexone. Methylnaltrexone is a quaternary amine derivative of naltrexone. Methylnaltrexone has been found to have only 2 to 4% of the opiate antagonistic activity of naltrexone in vivo due to its inability to pass the blood-brain-barrier and bind to the opiate receptors in the central nervous system.
Opioids are typically administered at a morphine equivalent dosage of: 0.005 to 0.15 mg/kg body weight for intrathecal administration; 0.05 to 1.0 mg/kg body weight for intravenous administration; 0.05 to 1.0 mg/kg body weight for intramuscular administration; 0.05 to 1.0 mg/kg body weight/hour for transmucosal or transdermal administration. By “morphine equivalent dosage” is meant representative doses of other opioids which equal one milligram of morphine, for example 10 mg meperidine, 1 mg methadone, and 80 μg fentanyl.
In accordance with the present invention, methylnaltrexone is administered at a dosage of: 0.1 to 40.0 mg/kg body weight for oral administration, including enteric coated methylnaltrexone.
The administration of the methylnaltrexone is preferably commenced prior to administration of the opioid to prevent opioid-induced inhibition of gastrointestinal motility or constipation. It is desirable to commence internal administration of methylnaltrexone about 20 minutes prior to administration of opioids in order to prevent these opioid-induced side effects. While the prevention of symptoms is preferred, methylnaltrexone administration may also be commenced after the administration of the opioid or after the onset of opioid induced symptoms as a treatment for those symptoms.
Methylnaltrexone is rapidly absorbed after oral administration from the stomach and bowel. Initial plasma levels of the drug are seen within 5-10 minutes of the administration of non-enteric coated compound. Addition of an enteric coating which prevents gastric absorption is associated with lower plasma levels of the methylnaltrexone. Surprisingly, the addition of an enteric coating (i.e., a coating which will prevent degradation or release in the stomach, but will release drug in the small and large bowel) enhances the efficacy of methylnaltrexone in the prevention of decreases in gut motility by intravenously administered opioids (morphine).
In a preferred embodiment for the prevention and/or treatment of constipation and inhibition of gastrointestinal motility, the QDNM or MNTX is enterically coated and administered orally. For oral administration, the QDNM or methylnaltrexone is formulated with pharmacologically acceptable binders to make a tablet or capsule with an enteric coating. An enteric coating is one which remains intact during passage through the stomach, but dissolves and releases the contents of the tablet or capsule once it reaches the small intestine. Most currently used enteric coatings are those which will not dissolve in low pH environments, but readily ionize when the pH rises to about 4 or 5, for example synthetic polymers such as polyacids having a pKa of 3 to 5.
The enteric coating may be made of any suitable composition. Suitable enteric coatings are described, for example, in U.S. Pat. No. 4,311,833 to Namikoshi, et al.; U.S. Pat. No. 4,377,568 to Chopra; U.S. Pat. No. 4,385,078 to Onda, et al.; U.S. Pat. No. 4,457,907 to Porter; U.S. Pat. No.4,462,839 to McGinley, et al.; U.S. Pat. No.4,518,433 to McGinley, et al.; U.S. Pat. No.4,556,552 to Porter, et al.; U.S. Pat. No. 4,606,909 to Bechgaard et al.; U.S. Pat. No. 4,615,885 to Nakagame, et al.; U.S. Pat. No. 4,670,287 to Tsuji; U.S. Pat. No. 5,536,507 to Abramowitz, et al.; U.S. Pat. No. 5,567,423 to Ying, et al.; U.S. Pat. No. 5,591,433 to Michael, et al.; U.S. Pat. No. 5,597,564 to Ying, et al.; U.S. Pat. No. 5,609,871 to Michael, et al.; U.S. Pat. No. 5,614,222 to Kaplan; U.S. Pat. No. 5,626,875 to Rodes, et al.; and U.S. Pat. No. 5,629,001 to Michael, et al., all of which are incorporated herein by reference.
Preferred enteric coating compositions include alkyl and hydroxyalkyl celluloses and their aliphatic esters, e.g., methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, hydroxyethylethylcellulose, hydroxyprophymethylcellulose, hydroxybutylmethylcellulose, hydroxypropylcellulose phthalate, hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose acetate succinate; carboxyalkylcelluloses and their salts, e.g., carboxymethylethylcellulose; cellulose acetate phthalate; cellulose acetate trimellitate, polycarboxymethylene and its salts and derivatives; polyvinyl alcohol and its esters: polyvinyl acetate phthalate; polycarboxymethylene copolymer with sodium formaldehyde carboxylate; acrylic polymers and copolymers, e.g., methacrylic acid-methyl methacrylic acid copolymer and methacrylic acid-methyl acrylate copolymer; edible oils such as peanut oil, palm oil, olive oil and hydrogenated vegetable oils; polyvinylpyrrolidone; polyethylene glycol and its esters; natural products such as shellac, and zein.
Other preferred enteric coatings include polyvinylacetate esters, e.g., polyvinyl acetate phthalate; alkyleneglycolether esters of copolymers such as partial ethylene glycol monomethylether ester of ethylacrylate-maleic anhydride copolymer or diethyleneglycol monomethylether ester of methylacrylate-maleic anhydride copolymer, N-butylacrylate-maleic anhydride copolymer, isobutylacrylate-maleic anhydride copolymer or ethylacrylate-maleic anhydride copolymer; and polypeptides resistant to degradation in the gastric environment, e.g., polyarginine and polylysine. Other suitable coatings and methods to make and use such formulations are well known to those skilled in the art (see, e.g., Remington: The Science and Practice of Pharmacy, 19th ed. (1995) Mack Publishing Company, Easton, Pa.; herein incorporated by reference).
Mixtures of two or more of the above compounds may be used as desired. The presently preferred enteric coating comprises cellulose acetate phthalate.
The enteric coating material may be mixed with various excipients including plasticizers such as triethyl citrate, acetyl triethyl citrate, diethyl phthalate, dibutyl phthalate, dibutyl subacute, dibutyl tartrate, dibutyl maleate, dibutyl succinate and diethyl succinate and inert fillers such as chalk or pigments.
The composition and thickness of the enteric coating may be selected to dissolve immediately upon contact with the digestive juice of the intestine. Alternatively, the composition and thickness of the external coating may be selected to be a time-release coating which dissolves over a selected period of time, as is well known in the art.
The amount of enteric coating depends on the particular enteric coating composition used and is preferably sufficient to substantially prevent the absorption of MNTX in the stomach.
Hydroxyalkyl celluloses and their aliphatic esters, carboxyalkyl celluloses and their salts, polycarboxymethylene and its salts and derivatives, polyvinyl alcohol and its esters, polycarboxymethylene copolymer with sodium formaldehyde carboxylates, poly-vinylpyrrolidone, and polyethylene glycol and its esters can be applied as enteric coatings by first dissolving the compound in a minimum amount of water. Alcohol is then added to the point of incipient cloudiness. The mixture can then be applied by conventional techniques.
Application of cellulose acetate phthalate may be accomplished by simply dissolving the cellulose acetate phthalate in a minimum amount of alcohol and then applying by conventional techniques. Hydrogenated vegetable oils may be applied by first dissolving the oil in a minimal amount of a non-polymer solvent, such as methylene chloride, chloroform or carbon tetrachloride, then adding alcohol to the point of incipient cloudiness and then applying by conventional techniques.
In a particularly preferred embodiment, the MNTX is coated with Eudragit L100 or S100, a methacrylic acid copolymer enteric coating, at a 50% coating level to provide stability at gastric pH and dissolution at gut pH per a US Pharmacopeia (USP) standard for enteric coatings.
In the above description, methylnaltrexone is used as an example of a particularly effective QDNM. It is apparent that other QDNM's may be used as desired.
The following Examples are intended to illustrate aspects of the invention and are not to be construed as limitations upon it. The methylnaltrexone used in the following Examples was manufactured by Mallinckrodt Pharmaceuticals, St. Louis, Mo. The Enteric Coating was manufactured by Coating Place, Inc., Verona, Wis.
Oral methylnaltrexone, whether enterically coated or uncoated, was shown to reverse the inhibitory effects of opioid administration on gastrointestinal motility as measured by oral-cecal transit time. As compared to non-enterically coated MNTX, however, treatment with enterically coated MNTX enhanced the efficacy of the drug at a lower dose while producing lower plasma levels of MNTX.
Subjects were divided into five treatment groups A-E. With the exception of subjects in Group A, who were given a placebo in place of morphine, all were given an intravenous dose of morphine at 0.05 mg/kg. Prior to morphine administration, subjects were given either a placebo or MNTX in various doses and formulations (see Table 1). The subjects in Group A and B were given a placebo in place of MNTX. Group C received uncoated MNTX at 6.4 mg/kg, Group D received enterically coated MNTX at 6.4 mg/kg active drug, and Group E received enterically coated MNTX at 3.2 mg/kg active drug. Table 1 shows the treatments for each group.
TABLE 1 Group Treatment combination FIG A placebo placebo B morphine placebo (0.05 mg/kg) C morphine methylnaltrexone uncoated (0.05 mg/kg) (6.4 mg/kg) D morphine methylnaltrexone enteric coated (0.05 mg/kg) (6.4 mg/kg active drug) E morphine methylnaltrexone enteric coated 0.05 mg/kg) (3.2 mg/kg active drug)
Plasma levels of MNTX were measured following administration of morphine and MNTX or placebo several times over the duration of the six hour monitoring period, at the times shown in
Oral-cecal transit time was used as a measure of gut motility and propensity for constipation. Oral-cecal transit time was measured by the lactulose-breath hydrogen method. Group A demonstrated normal transit times as previously described in the literature (Yuan et al. (1996) Clin. Pharmacol. Ther. 59:469-475; Yuan et al. (1997) Clin. Pharmacol. Ther. 61:467-475). Group B had prolongation of their oral-cecal transit times by 50-100%, while Groups C (
As demonstrated in
As with most drugs, it is desirable to maintain the lowest possible systemic levels of MNTX which are sufficient to provide the desired therapeutic effect. For example, elevated circulating levels of MNTX can result in orthostatic hypotension. The present discovery provides an unexpected means to avoid such undesirable drug side effects by lowering the dose administered and subsequently minimizing circulating levels of the drug. Since endogenous and externally supplied opioid-induced inhibition of gastrointestinal motility and constipation is thought to result from opioid receptors located within the gastrointestinal tract, enterically coated MNTX or other QDNMs may provide a local administration of the drug that does not require a circulating level for effective prevention or treatment of symptoms. Thus, the amount and/or frequency of drug administered can be reduced.
The preceding description and Examples are intended to be illustrative. Those skilled in the art to which the invention pertains will appreciate that alterations and changes in the described protocols may be practiced without departing from the meaning, spirit, and scope of this invention. Therefore, the foregoing description should be read consistent with and as support to the following claims, which are to have their fullest and fair scope.
|Brevet cité||Date de dépôt||Date de publication||Déposant||Titre|
|US2003 *||12 mars 1841||Improvement in horizontal windivhlls|
|US222911 *||11 mars 1879||23 déc. 1879||Improvement in book-cases|
|US1047726 *||12 mars 1912||17 déc. 1912||Anthony J Yoggerst||Pipe-cleaner.|
|US2625457 *||26 juil. 1951||13 janv. 1953||Bernard J Baecher||Course recorder|
|US4176186 *||28 juil. 1978||27 nov. 1979||Boehringer Ingelheim Gmbh||Quaternary derivatives of noroxymorphone which relieve intestinal immobility|
|US4311833 *||29 févr. 1980||19 janv. 1982||Daicel Chemical Industries Ltd.||Process for preparing ethylcarboxymethylcellulose|
|US4322426 *||28 avr. 1980||30 mars 1982||E. I. Du Pont De Nemours And Company||17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists|
|US4377568 *||12 août 1981||22 mars 1983||Merck Sharp & Dohme (I.A.) Corp.||Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same|
|US4385078 *||30 août 1979||24 mai 1983||Shin-Etsu Chemical Co., Ltd.||Method for providing enteric coating on solid dosage forms and aqueous compositions therefor|
|US4457907 *||5 août 1982||3 juil. 1984||Clear Lake Development Group||Composition and method for protecting a therapeutic drug|
|US4462839 *||16 juin 1983||31 juil. 1984||Fmc Corporation||Enteric coating for pharmaceutical dosage forms|
|US4518433 *||8 nov. 1982||21 mai 1985||Fmc Corporation||Enteric coating for pharmaceutical dosage forms|
|US4556552 *||19 sept. 1983||3 déc. 1985||Colorcon, Inc.||Enteric film-coating compositions|
|US4606909 *||20 juin 1984||19 août 1986||A/S Alfred Benzon||Pharmaceutical multiple-units formulation|
|US4615885 *||9 oct. 1984||7 oct. 1986||Terumo Kabushiki Kaisha||Pharmaceutical composition containing urokinase|
|US4670287 *||14 févr. 1986||2 juin 1987||Washu Kirai Kogyo Kabushiki Kaisha||Method of film-coating hard capsules|
|US4719215 *||7 mars 1986||12 janv. 1988||University Of Chicago||Quaternary derivatives of noroxymorphone which relieve nausea and emesis|
|US4857833 *||27 août 1987||15 août 1989||Teradyne, Inc.||Diagnosis of faults on circuit board|
|US4861781 *||3 sept. 1987||29 août 1989||The University Of Chicago||Quaternary derivatives of noroxymorphone which relieve nausea and emesis|
|US4888346 *||4 déc. 1987||19 déc. 1989||Bernard Bihari||Method for the treatment of persons infected with HTLV-III (AIDS) virus|
|US4965269 *||20 déc. 1989||23 oct. 1990||Ab Hassle||Therapeutically active chloro substituted benzimidazoles|
|US4987136 *||12 févr. 1986||22 janv. 1991||The Rockefeller University||Method for controlling gastrointestinal dysmotility|
|US5102887 *||15 juin 1990||7 avr. 1992||Arch Development Corporation||Method for reducing emesis and nausea induced by the administration of an emesis causing agent|
|US5159081 *||29 mars 1991||27 oct. 1992||Eli Lilly And Company||Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists|
|US5202159 *||31 déc. 1990||13 avr. 1993||Standard Chemical & Pharmaceutical Corp., Ltd.||Preparation method of microdispersed tablet formulation of spray-dried sodium diclofenac enteric-coated microcapsules|
|US5270328 *||29 juin 1992||14 déc. 1993||Eli Lilly And Company||Peripherally selective piperidine opioid antagonists|
|US5391372 *||28 juin 1993||21 févr. 1995||Campbell; Elizabeth||Methods of treating colic and founder in horses|
|US5426112 *||23 févr. 1993||20 juin 1995||Scully, Scott, Murphy & Presser, P.C.||Growth regulation and related applications of opioid antagonists|
|US5472943 *||27 juil. 1993||5 déc. 1995||Albert Einstein College Of Medicine Of Yeshiva University,||Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists|
|US5512578 *||19 juil. 1994||30 avr. 1996||Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University||Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists|
|US5536507 *||24 juin 1994||16 juil. 1996||Bristol-Myers Squibb Company||Colonic drug delivery system|
|US5567423 *||19 avr. 1994||22 oct. 1996||Enzacor Properties, Ltd.||Animal growth promotant|
|US5591433 *||20 janv. 1995||7 janv. 1997||University Of Cincinnati||Oral administration of immunologically active biomolecules and other therapeutic proteins|
|US5597564 *||26 juil. 1994||28 janv. 1997||Enzacor Properties Limited||Method of administering a microgranular preparation to the intestinal region of animals|
|US5609871 *||26 oct. 1994||11 mars 1997||Michael; J. Gabriel||Oral administration of therapeutic proteins for treatment of infectious disease|
|US5614219 *||4 déc. 1992||25 mars 1997||Alfatec-Pharma Gmbh||Oral administration form for peptide pharmaceutical substances, in particular insulin|
|US5614222 *||25 oct. 1994||25 mars 1997||Kaplan; Milton R.||Stable aqueous drug suspensions and methods for preparation thereof|
|US5626875 *||27 avr. 1995||6 mai 1997||Esteve Quimica, S.A.||Stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation|
|US5629001 *||30 janv. 1995||13 mai 1997||University Of Cincinnati||Oral administration of therapeutic proteins for treatment of infectious disease|
|US5656290 *||17 mai 1995||12 août 1997||The Procter & Gamble Company||Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery|
|US5767125 *||3 déc. 1996||16 juin 1998||Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University||Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists|
|US5804595 *||5 déc. 1995||8 sept. 1998||Regents Of The University Of Minnesota||Kappa opioid receptor agonists|
|US5811451 *||22 mai 1995||22 sept. 1998||Minoia; Paolo||Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies|
|US5866154 *||25 juin 1996||2 févr. 1999||The Dupont Merck Pharmaceutical Company||Stabilized naloxone formulations|
|US5866164 *||12 mars 1997||2 févr. 1999||Alza Corporation||Composition and dosage form comprising opioid antagonist|
|US5958452 *||10 avr. 1997||28 sept. 1999||Euro-Celtique, S.A.||Extruded orally administrable opioid formulations|
|US5972954 *||3 nov. 1997||26 oct. 1999||Arch Development Corporation||Use of methylnaltrexone and related compounds|
|US6025154 *||6 juin 1995||15 févr. 2000||Human Genome Sciences, Inc.||Polynucleotides encoding human G-protein chemokine receptor HDGNR10|
|US6096756 *||16 juin 1998||1 août 2000||Albert Einstein College Of Medicine Of Yeshiva University||Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists|
|US6194382 *||3 mars 1999||27 févr. 2001||Albert Einstein College Of Medicine Of Yeshiva University||Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists|
|US6261599 *||23 juil. 1999||17 juil. 2001||Euro-Celtique, S.A.||Melt-extruded orally administrable opioid formulations|
|US6274591 *||22 juil. 1998||14 août 2001||Joseph F. Foss||Use of methylnaltrexone and related compounds|
|US6353004 *||9 oct. 1998||5 mars 2002||Adolor Coporation||Peripherally acting anti-pruritic opiates|
|US6395705 *||4 janv. 2001||28 mai 2002||Albert Einstein College Of Medicine Of Yeshiva University||Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists|
|US6419959 *||4 déc. 1997||16 juil. 2002||Klinge Pharma Gmbh||Galenic composition containing opioid antagonists|
|US6451806 *||29 nov. 2000||17 sept. 2002||Adolor Corporation||Methods and compositions involving opioids and antagonists thereof|
|US6455537 *||25 août 2000||24 sept. 2002||Barrett R. Cooper||Methods for treating opiate intolerance|
|US6469030 *||29 nov. 2000||22 oct. 2002||Adolor Corporation||Methods for the treatment and prevention of ileus|
|US6559158 *||26 sept. 2000||6 mai 2003||Ur Labs, Inc.||Use of methylnaltrexone and related compounds to treat chronic opioid use side affects|
|US6608075 *||21 mai 2001||19 août 2003||The University Of Chicago||Use of methylnaltrexone and related compounds|
|US20010018413 *||4 janv. 2001||30 août 2001||Crain Stanley M.||Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists|
|US20010033865 *||22 juil. 1999||25 oct. 2001||Benjamin Oshlack||Melt-extrusion multiparticulates|
|US20010036476 *||6 févr. 2001||1 nov. 2001||Euro-Celtique S.A.||Melt-extruded orally administrable opioid formulations|
|US20010036951 *||29 nov. 2000||1 nov. 2001||Farrar John J.||Novel methods for the treatment and prevention of ileus|
|US20010047005 *||29 nov. 2000||29 nov. 2001||Farrar John J.||Novel methods and compositions involving opioids and antagonists thereof|
|US20020028825 *||21 mai 2001||7 mars 2002||Foss Joseph F.||Use of methylnaltrexone and related compounds|
|US20020188005 *||13 juin 2002||12 déc. 2002||Adolor Corporation||Novel methods for the treatment and prevention of ileus|
|US20030065003 *||23 oct. 2002||3 avr. 2003||The University Of Chicago||Use of methylnaltrexone and related compounds|
|US20030191147 *||9 avr. 2002||9 oct. 2003||Barry Sherman||Opioid antagonist compositions and dosage forms|
|US20040167148 *||24 févr. 2004||26 août 2004||Foss Joseph F.||Oral use of methylnaltrexone and related compounds to treat constipation in chronic opioid users|
|USRE36547 *||13 janv. 1996||1 févr. 2000||Albert Einstein College Of Medicine Of Yeshiva University||Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists|
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|US7563899||25 mai 2006||21 juil. 2009||Progenics Pharmaceuticals, Inc.||(S)-N-methylnaltrexone|
|US7674904||25 mai 2006||9 mars 2010||Progenics Pharmaceuticals, Inc.||Synthesis of R-N-methylnaltrexone|
|US9102680||21 nov. 2012||11 août 2015||Wyeth Llc||Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof|
|US20040162306 *||12 févr. 2004||19 août 2004||Foss Joseph F.||Use of methylnal trexone and related compounds to treat constipation in chronic opioid users|
|US20040162307 *||12 févr. 2004||19 août 2004||Foss Joseph F.||Use of methylnaltrexone and related compounds to induce laxation in chronic opioid users|
|US20040162308 *||12 févr. 2004||19 août 2004||Foss Joseph F.||Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids|
|US20040167148 *||24 févr. 2004||26 août 2004||Foss Joseph F.||Oral use of methylnaltrexone and related compounds to treat constipation in chronic opioid users|
|US20040259899 *||8 avr. 2004||23 déc. 2004||Sanghvi Suketu P.||Combination therapy for constipation|
|US20040266806 *||8 avr. 2004||30 déc. 2004||Sanghvi Suketu P.||Pharmaceutical formulation|
|US20050004155 *||8 avr. 2004||6 janv. 2005||Boyd Thomas A.||Use of methylnaltrexone to treat irritable bowel syndrome|
|Classification aux États-Unis||424/471, 424/472, 514/282|
|20 janv. 2006||AS||Assignment|
Owner name: PROGENICS PHARMACEUTICALS NEVADA, INC., NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UR LABS, INC.;REEL/FRAME:017480/0272
Effective date: 20051222